Premium
Incidence of interstitial lung disease in patients with mesothelioma in the west part of Japan
Author(s) -
Nojiri Shuko,
Gemba Kenichi,
Aoe Keisuke,
Kato Katsuya,
Yamaguchi Takuhiro,
Sato Tsugumichi,
Kubota Kiyoshi,
Kishimoto Takumi
Publication year - 2011
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.2123
Subject(s) - medicine , interstitial lung disease , rate ratio , incidence (geometry) , mesothelioma , exacerbation , poisson regression , adverse effect , retrospective cohort study , population , surgery , confidence interval , lung , pathology , physics , environmental health , optics
Purpose In order to evaluate the incidence of an adverse event encountered when using a new therapeutic intervention, it is essential to know the background rate of this adverse event in the same patient population. Interstitial lung disease (ILD) often develops in Japanese patients receiving treatment with anti‐neoplastic agents or other drugs. In our study, we estimated the background rate of ILD in patients with malignant mesothelioma (MM). Methods We conducted a retrospective cohort study of 328 Japanese patients diagnosed with MM during the period between 1996 and 2006. Results After the diagnosis of MM had been made, 21 (15 new and 6 exacerbation) of the 328 patients developed ILD. The crude baseline rate of ILD was estimated to be 0.023 (95%CI, 0.009–0.054) per patient‐year, and the baseline rate using the Poisson regression model was estimated to be 0.032 (95%CI, 0.017–0.059) per patient‐year where major therapeutic interventions were incorporated in the model. The risk of ILD was increased by surgical excision (rate ratio, 8.87; 95%CI, 2.39–33.0), pleurodesis with picibanil (rate ratio, 5.14; 95%CI, 1.63–16.3), and systemic chemotherapy using vinorelbine (rate ratio, 5.95; 95%CI, 1.22–29.0). Conclusions Our results have implications for evaluating the safety outcomes of future studies in patients receiving treatment for MM. The development of ILD in such studies at an incidence rate higher than 0.02–0.03 per patient‐year might indicate an excess occurrence as a result of a therapeutic intervention. Copyright © 2011 John Wiley & Sons, Ltd.